The global alopecia areata treatment market can be segmented based on therapy type, distribution channel, and region. In terms of therapy type, the alopecia areata treatment market can be classified into steroids, vasodilator, anti-Inflammatory drugs, immunosuppressive drugs, UV light therapy, and others. Corticosteroid drugs is a rapidly expanding segment due to anti-inflammatory and lipid-regulating properties which is also increasingly used in clinical trials across the globe. In terms of distribution channel, the global alopecia areata treatment market can be categorized into online pharmacies, hospital pharmacies, retail pharmacies, and others.
In terms of region, the global alopecia areata treatment market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominated the global alopecia areata treatment market in 2017 due to increase in funding for development of research and health care infrastructure. Increase in incidence of hair fall diseases such as alopecia areata and early phase diagnosis & treatment drive the biotechnology & pharmaceutical market, which in turn is expected to boost the alopecia areata treatment market in North America. Europe was the second largest market for alopecia areata treatment in 2017 owing to favorable government policies for expansion of health care infrastructure and hair treatment companies. The alopecia areata treatment market in Asia Pacific is likely to expand at a high CAGR during the forecast period due to increase in young population with alopecia areata disorder, changing lifestyle, rise in awareness among patients, and surge in per capita expenditure. Additionally, economic growth in India and China supports health care infrastructure and expansion of pharmaceutical companies and biotech labs.
Major players operating in the global alopecia areata treatment market include Pfizer, Inc., TetraLogic Pharmaceuticals Corporation, Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals, Perrigo Company plc, Teva Pharmaceutical Industries Ltd., and Schering-Plough Corporation.
Request For TOC: